Table 3.

Cytopenias reported during venetoclax monotherapy or up to 30 days posttreatment

Subgroups of interest
All patientsdel(17p) CLLPrior BCRi
Event, n (%)N = 350n = 211an = 148a
Neutropenia141 (40)83 (39)54 (37)
 Grade 3/4128 (37)76 (36)47 (32)
 SAE6 (1.7)5 (2)2 (1.4)
 Leading to dose reduction17 (5)13 (6)4 (3)
 Leading to dose interruption14 (4)10 (5)4 (3)
 Leading to discontinuation1 (0.3)00
Anemiab109 (31)62 (29)57 (39)
 Grade 3/460 (17)33 (16)33 (22)
 SAE5 (1.4)3 (1)1 (0.7)
 Leading to dose reduction1 (0.3)01 (0.7)
 Leading to dose interruption1 (0.3)00
 Leading to discontinuation000
Thrombocytopenia74 (21)46 (22)34 (23)
 Grade 3/449 (14)30 (14)23 (16)
 SAE6 (1.7)5 (2)2 (1.4)
 Leading to dose reduction3 (0.9)2 (0.9)0
 Leading to dose interruption8 (2)5 (2)3 (2)
 Leading to discontinuation2 (0.6)2 (0.9)0
  • Abbreviation: BCRi, B-cell receptor pathway inhibitors (ibrutinib, idelalisib, or investigational compounds).

  • aSubgroups include patients across all three clinical studies. The 211 patients with del(17p) CLL and 148 patients who received prior BCRi are not mutually exclusive and do not add up to the 350 patients included in the overall integrated dataset.

  • bIncludes the Medical Dictionary for Regulatory Activities (MedDRA) preferred term “anemia” and does not include events of autoimmune hemolytic anemia.